Insight Molecular Diagnostics Inc. Impairment of Intangible Assets (Excluding Goodwill)
Insight Molecular Diagnostics Inc. (IMDX) reported Impairment of Intangible Assets (Excluding Goodwill) of $625.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2019-04-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2019-04-01
- Insight Molecular Diagnostics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2018-12-31 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2018-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of intangible assets (excluding goodwill) for fiscal 2018 was $625.00K.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $0.00 derived: sum of 2 quarters · filed 2019-04-01 | $625.00K 10-K · filed 2019-04-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $625.00K 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | $625.00K 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |